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Gastrointestinal stromal tumors are rare soft-tissue neoplasms, the incidence of which 
is 1–3% of all malignant gastrointestinal tumors. Tumor size is reported to be a major 
determinant of recurrence in patients with resectable gastrointestinal stromal tumors. 
Here, we describe our experience in managing a large extra-gastrointestinal stromal 
tumor arising from the retroperitoneum.
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The term gastrointestinal stromal tumor (GIST) was first 
introduced by Mazur and Clark1 to describe gastrointesti-
nal non-epithelial tumors lacking microscopic evidence of 
smooth muscles or characteristics of neural immunore-
activity. They are thought to originate from the interstitial 
cells of Cajal, and are relatively rare soft-tissue neoplasms 
with an estimated incidence of 14.5 per 1,000,000 pa-
tients affected.2 They are most commonly found in the 
stomach (50–60%), small intestines (20–30%), colon and 
rectum (10%), and esophagus (5%).3
As vascular tumors, GISTs primarily present with gas-
trointestinal bleeding (50%), palpable mass (35%, some-
times with obstructive features), pain (20%) and, rarely, 
as an incidental finding. These lesions often present with 
only nonspecific symptoms such as bloating and early 
satiety unless they ulcerate, bleed, or grow large enough 
to cause pain or obstruction.4
In contrast to GIST, extra-gastrointestinal stromal tumor 
(EGIST) represents an unusual location of GIST without 
clinical evidence of a gastrointestinal primary, and is ex-
ceedingly rare. Although the majority of GISTs are lo-
cated in the GI tract, some GISTs occur in the omentum, 
mesentery and retroperitoneum.4 However, EGIST of the 
prostate and urinary bladder, associated with urinary tract 
symptoms, have been reported.5,6 Here, we report the 
case of a 47-year-old man diagnosed with primary retro-
peritoneal EGIST and describe our experience in the 
management of the large EGIST.
2.  Case Report
A 47-year-old male consulted at the Urology Outpatient 
Clinic for complaints of progressive dysuria and consti-
pation for 7 months. There was no gross hematuria or 
bloody stool. The patient denied having any other medical 
history except for right herniorrhaphy for right inguinal 
hernia in September 2006. Physical examination revealed 
a large, fixed and firm non-tender mass protruding from 
the lower abdomen. There were also varicoceles noted 
over bilateral spermatic cords symmetrically. Magnetic 
resonance imaging demonstrated a pelvic mass about 
20 ˜  10 ˜  10 cm in size, causing left-sided displacement of 
the rectum and urinary bladder (Figure 1). Colonoscopy 
and cystoscopy revealed external compression of the 
mass without evidence of invasion.
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Figure 1 (A) Sagittal view of T1-weighted magnetic resonance imaging with contrast revealed a large pelvic mass with diffuse 
enhancement. Suspicious hypo-enhanced septae were also noted (arrowheads). (B) Coronal view of T2-weighted magnetic reso-
nance imaging revealed a large hyperintense mass at the midline of the pelvis with suspicious hypointense septae (arrows) and 
bright necrotic foci (arrowheads). The bladder was compressed and displaced to the left (asterisks).
The hypervascular pelvic tumor adhered tightly to 
the urinary bladder. Hence, exploratory laparotomy for 
en bloc resection of the tumor, urinary bladder and 
prostate was performed. A 4-cm long laceration injury of 
the low rectum was noted perioperatively and was re-
paired with 3-0 silk interrupted sutures. Loop sigmoid 
colostomy over the left lower quadrant of the abdomi-
nal area and ileal conduit over the right lower quadrant 
were then performed.
Postoperatively, the patient was transferred to the 
intensive care unit for 2 days of close monitoring. Partial 
parenteral nutrition was started on the 4th postopera-
tive day for ileus, which subsided on the 9th day. He was 
discharged on the 13th day. Chest X-ray, abdominal sonog-
raphy and abdominal computed axial tomography were 
performed every 6 months thereafter. In addition, physical 
examination was done every 2 months. He was disease-
free with no evidence of local recurrence or distant me-
tastases at the 30-month follow-up.
Grossly, the soft tissue tumor measured 16 ˜  10 ˜  9 cm, 
was encapsulated, and was elastic-to-firm with multi-
lobular and flesh-colored cut surface. Hemorrhage and 
necrosis were not obvious. There was no evidence 
of involvement of the gastrointestinal tract, omentum, 
mesentery, prostate, seminal vesicle or urinary bladder. 
Microscopically, the tumor was composed of nests and 
sheets of epithelioid cells bearing pale-to-eosinophilic 
cytoplasm and round-to-ovoid nuclei with indistinct cell 
borders. There was some degree of nuclear atypia with 
increased mitotic activity. Vascular spreading was focally 
seen but tumor necrosis was not obvious (Figure 2).
Immunohistochemical studies showed that the tumor 
cells were negative for cytokeratin, CD117, S100, desmin 
and smooth muscle actin (Figure 2). The tumor cells only 
expressed vimentin, CD34 and CD99. According to the 
results of immunohistochemical and histologic examina-
tions, carcinoma, neurogenic tumor and smooth muscle 
neoplasm were excluded. However, the possibility of EGIST 
was considered due to the epithelioid morphology, 
which is a frequent histologic finding of CD117(–) GISTs.
Subsequent KIT and platelet-derived growth factor 
receptor-α (PDGFRA) mutational analysis by polymerase 
chain reaction failed to reveal any detectable mutation 
in both genes. According to the literature, about 10% 
of GISTs have wild-type KIT and PDGFRA genes, and 
probably a different pathogenetic pathway leading to 
tumor formation. Our case may belong to this subgroup 
after excluding other soft tissue tumor entities. Thus, 
primary retroperitoneal EGIST was still considered.
3.  Discussion
EGISTs are a group of GISTs that are located at unusual 
sites without clinical evidence of a gastrointestinal pri-
mary. The clinical, pathological and prognostic features 
of GISTs are widely known, while there is a paucity of 
data on EGISTs. Most EGISTs arise from the omentum 
and mesentery, and have immunopathologic compara-
bility with GISTs in the digestive tract. In a series by Agaimy 
and Wunsch,7 14 of 200 cases with typical morphologic 
and immunohistochemical features of GIST were initially 
described as EGIST. However, after detailed review of 
the so-called EGISTs, associated gastrointestinal mucosa 
was found to be present. EGIST also arises in the retro-
peritoneum, although the incidence is exceedingly rare.8 
Other unusual origins, such as the prostate and urinary 
bladder, have likewise been reported. Clinicians should 
therefore be aware of this possibility when a retroperi-
toneal mass is encountered.
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GISTs show lineage differentiation similar to the 
interstitial cells of Cajal and frequently express CD117 
(KIT protein) diffusely and strongly. Microscopically, tumor 
cells in GISTs are usually spindle- or epithelioid-shaped. 
However, there are morphologic mimics simulating car-
cinoma, smooth muscle neoplasm, neurogenic tumor, 
and plasmacytoma. Under such circumstances, a careful 
histologic examination with immunohistochemical study 
using a panel of markers, or even gene mutational anal-
ysis, is indicated.
In immunohistochemical studies, GISTs are more 
often positive for CD117, CD34 and smooth muscle actin 
than for cytokeratin, desmin and S100. A small portion 
of GISTs lacks CD117 expression. Most of them have mu-
tant PDGFRA gene and epithelioid features.9 Most GISTs 
also have gain-of-function mutation of CD117 (80–85%), 
although some demonstrate mutation of the PDGFRA 
gene (5–10%). About 10% have wild-type KIT and PDGFRA 
genes.10 In GISTs lacking KIT and PDGFRA mutations, 
there are probably other mechanisms that lead to tumor 
formation.
The histologic features and immunophenotype of 
EGISTs are similar to those of GISTs, showing mainly spin-
dle or epithelioid cytomorphology, as well as CD117 (100%) 
and CD34 (50%) reactivity.11 There are limited data on 
the cytogenetic and mutational status of EGISTs. Instead, it 
is presumed that they possess similar findings as GISTs.12
EGISTs and GISTs are often asymptomatic until they 
reach a large size and cause mass effect, bleeding or 
rupture. Some patients with EGISTs have been diag-
nosed by transrectal ultrasound-guided prostate biopsy 
due to abnormal findings on digital rectal examination. 
Neoadjuvant therapy with imatinib mesylate followed 
by prostatectomy have been performed; results indicate 
partial response and disease stability longer than 12 
months, with updated data showing a disease-free sur-
vival of 65% at 21 months.2 However, the possibility of 
tumor spread or rupture, abscess formation, or fecal fis-
tula should be a preoperative concern before surgical 
biopsy. In addition, biopsy may incompletely sample the 
lesion and a false diagnosis is possible in some cases. 
Therefore, this should not be performed if the tumor is 
potentially resectable.
Except for those that are unresectable or metastatic, 
surgery remains the standard treatment for EGIST.13 
Complete en bloc removal of EGIST and the surrounding 
organs that are involved is required. The recurrence rate 
after surgery in reported series ranges from 17% to 24%.2 
Historically, surgery is considered to be the only effective 
therapy because GISTs are known to be resistant to con-
ventional cytotoxic chemotherapeutic regimens. Recently, 
promising results from several studies have led to the in-
troduction of targeted therapy—imatinib (a c-kit tyrosine 
kinase inhibitor)—for treating GISTs, after it was proven to 
Figure 2 (A) The tumor grew in a lobular pattern and formed 
sheets and nests with epithelioid features (hematoxylin & eosin, 
40×). (B) Increased mitotic activity with nuclear atypia was noted 
(hematoxylin & eosin, 400×). (C) Immunohistochemical stain of 
tumor cells was negative for CD117 (400×).
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be safe and efficacious. Targeted therapy is indicated and 
effective for positive KIT and unresectable or metastatic 
GISTs as adjuvant or neoadjuvant therapy.14 However, in 
cases of negative immunohistochemical staining for c-kit 
and tumor-free surgical margins, additional treatment 
with imatinib or chemotherapy is not indicated.
In the past, numerous retrospective analyses have 
tried to identify prognostic factors. Only tumor size and 
the presence of mitotic figures have been accepted as 
the most useful predictive factors of poor outcome with 
good reproducibility and statistical consistency. In a ret-
rospective study of 100 patients with resectable GISTs, mul-
tivariate analysis demonstrated that tumor size > 10 cm 
was associated with higher recurrence rates (p = 0.032) 
and was the only independent prognostic factor of poor 
survival (p = 0.020).
A follow-up protocol is recommended, which should 
include abdominal sonography and abdominal com-
puted axial tomography every 6 months in the first year 
and annually thereafter, or whenever recurrence is sus-
pected.15 Due to the large size of the EGIST, our patient 
needed close follow-up.
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